CORRECTING and REPLACING Svante Recognized as One of the World's Top GreenTech Companies by TIME and Statista
10.4.2025 03:24:00 CEST | Business Wire | Press Release
A multimedia asset accompanying this release has been removed.
The release reads:
SVANTE RECOGNIZED AS ONE OF THE WORLD'S TOP GREENTECH COMPANIES BY TIME AND STATISTA
- Leading carbon capture and removal technology provider, Svante, named on TIME and Statista’s list of the World's Top GreenTech Companies of 2025
- Svante is one of only five Canadian companies who made the list
- The analysis by TIME, in partnership with data firm Statista, considered the positive impact, financial strength, and innovation of more than 8,000 companies developing products, services, or technologies to reverse the impact of human activities on the planet.
Svante Technologies Inc. (Svante), a pioneer in carbon capture and removal structured adsorbent filter technology, has been named one of the "World's Top GreenTech Companies of 2025" by TIME and Statista. This prestigious accolade recognizes Svante's transformative impact on industrial sustainability efforts and its position at the forefront of the green technology revolution.
Selected from a pool of over 8,000 companies worldwide, Svante stands out as one of only five Canadian firms to make the list. This recognition underscores the company's significant contributions to developing innovative engineered solutions that address urgent carbon management challenges.
Claude Letourneau, President and CEO of Svante, expressed his enthusiasm about the honor: "This acknowledgment is a testament to our team's unwavering commitment to pioneering sustainable carbon capture and removal solutions. As we launch our first gigafactory in Vancouver, capable of producing enough filters to capture 10 million tonnes of CO2 annually, we're catalyzing a new era: a rewiring of the industrial sector so that it can make low carbon intensity products by leveraging our innovative technology that can stop CO2 from going into the atmosphere and equally remove it from the ambient air."
Svante's groundbreaking structured adsorbent filter technology offers industries a commercially viable and environmentally responsible solution for capturing and removing CO2 from both industrial emissions and the atmosphere (called direct air capture or DAC). The trapped CO2 can be permanently stored underground or repurposed into other products ranging from sustainable aviation fuel to industrial products and consumer goods.
The company's innovative approach has garnered attention across various sectors, including pulp & paper, cement, steel, oil & gas, and DAC. Svante was recently inducted into the Cleantech Group’s Global Cleantech 100 Hall of Fame and has also been featured on the XPRIZE’s XB100 World’s Top Deep Tech Companies list. The company’s inclusion in the World's Top GreenTech Companies of 2025 list further cements its status as a global leader in carbon management.
As Svante continues to expand its operations and optimize its unique technology, the recognition from TIME and Statista serves as a powerful endorsement of the company's vision and potential to drive significant positive change in the world’s ability to manage CO2 emissions.
About Svante
Svante is a purpose-driven, leading carbon capture and removal solutions provider. The Vancouver, Canada-based company manufactures nanoengineered filters and modular rotary contactor machines that capture and remove CO2 from industrial emissions and the air in an environmentally responsible manner. Svante is on the 2025 Global Cleantech 100 and was recently inducted into the Global Cleantech 100 Hall of Fame. The company has also been named as an XPRIZE Foundation XB100 – World’s Top 100 Private Deep Tech Companies and was ranked second among private companies in the Corporate Knights’Future 50 Fastest Growing Sustainable (Private) Companies.
For more Information, visit www.svanteinc.com and follow Svante on LinkedIn at www.linkedin.com/svantesolutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250326932660/en/
Contacts
Colleen Nitta
Director, Marketing & Communications
Svante
+1-604-970-2813
cnitta@svanteinc.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom